Fortress Biotech (NASDAQ:FBIO) CEO Lindsay Md Rosenwald Buys 64,491 Shares of Stock

Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CEO Lindsay Md Rosenwald purchased 64,491 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were acquired at an average price of $1.80 per share, for a total transaction of $116,083.80. Following the acquisition, the chief executive officer directly owned 4,651,332 shares in the company, valued at $8,372,397.60. This represents a 1.41% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fortress Biotech Trading Down 5.7%

Shares of NASDAQ:FBIO opened at $1.78 on Friday. The stock has a market capitalization of $60.16 million, a PE ratio of 0.78 and a beta of 1.27. Fortress Biotech, Inc. has a 1 year low of $1.64 and a 1 year high of $4.53. The firm has a fifty day moving average price of $2.07 and a 200 day moving average price of $2.69. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last posted its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $21.57 million. Analysts expect that Fortress Biotech, Inc. will post 2.66 EPS for the current fiscal year.

Fortress Biotech News Summary

These are some of the FBIO news items that stood out recently:

  • Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares in transactions from November 17–19, investing about $340,000. The purchases increased both executives’ holdings and may signal confidence in the company, though insider buying alone does not establish a change in business outlook. CEO filing CFO filing
  • Neutral Sentiment: Zacks initiated coverage with a “hold” rating, offering no clear bullish or bearish signal. Zacks ratings
  • Neutral Sentiment: HC Wainwright estimates earnings per share of $2.66 for FY2026, in line with consensus, and $2.37 for FY2027. The lower projected figure for 2027 may temper optimism, but these are analyst estimates rather than company guidance. HC Wainwright estimate coverage

Institutional Investors Weigh In On Fortress Biotech

Several hedge funds have recently made changes to their positions in FBIO. Squarepoint Ops LLC acquired a new stake in Fortress Biotech during the second quarter worth about $47,000. Renaissance Technologies LLC raised its holdings in Fortress Biotech by 22.8% in the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 18,490 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Fortress Biotech in the 3rd quarter valued at approximately $462,000. Institutional investors own 96.51% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on FBIO. Zacks Research assumed coverage on Fortress Biotech in a research report on Wednesday. They issued a “hold” rating on the stock. Weiss Ratings downgraded shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Finally, Wall Street Zen downgraded shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Fortress Biotech presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Get Our Latest Analysis on FBIO

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Further Reading

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.